10-Q: bioAffinity Technologies Faces Nasdaq Delisting Warning Amidst Financial Woes

bioAffinity Technologies reports increased revenue for its CyPath Lung diagnostic test but faces substantial doubt about its going concern status and a Nasdaq delisting warning.

Summary

• bioAffinity Technologies filed its Form 10-Q for the quarterly period ended June 30, 2026.
• The company reported net revenue of $1.51 million for Q2 2026, a 19% increase from $1.27 million in Q2 2025, driven by CyPath Lung testing revenue growth.
• However, the company incurred a net loss of $3.37 million for Q2 2026, compared to $4.06 million in Q2 2025.
• For the six months ended June 30, 2026, net revenue decreased by 8% to $2.86 million from $3.12 million in the prior year period, while the net loss increased to $7.00 million from $6.72 million.
• The company has an accumulated deficit of approximately $75.6 million as of June 30, 2026.
• Management has concluded there is substantial doubt about the company's ability to continue as a going concern.
• bioAffinity Technologies received a Nasdaq delisting warning due to its stock bid price falling below $1.00 for 30 consecutive business days.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the company's continued significant losses, accumulated deficit, and substantial doubt about its ability to continue as a going concern, despite some revenue growth in its diagnostic test.

Positives

• Unit sales for CyPath Lung diagnostic in Q2 2026 grew 216% compared to Q2 2025.
• CyPath Lung testing revenue increased 156% to $835,000 for the six months ended June 30, 2026, compared to $323,000 in the prior year period.
• The number of physician offices and clinics ordering CyPath Lung increased by 122% in Q2 2026 compared to the same period in 2025.
• The company raised approximately $3.2 million in gross proceeds from an equity offering in Q2 2026.
• The company announced a collaboration with Pictor, Inc. to support the development and commercialization of next-generation diagnostic tests.
• Positive results from preliminary therapeutic studies for topical treatments for squamous and basal cell skin cancers were presented.

Negatives

• The company has an accumulated deficit of $75.6 million as of June 30, 2026.
• Management has concluded there is substantial doubt about the company's ability to continue as a going concern.
• The company's cash and cash equivalents were $2.4 million as of June 30, 2026, and expected to support operations only through August 2026.
• bioAffinity Technologies received a Nasdaq delisting warning due to its stock bid price closing below $1.00 for 30 consecutive business days.
• Net loss for the six months ended June 30, 2026, increased to $7.0 million from $6.7 million in the prior year period.
• Selling, general and administrative expenses increased by 31% to $6.1 million for the six months ended June 30, 2026, compared to $4.7 million in the prior year period.

Risks

• The company's business plan relies on obtaining additional capital and financing; failure to do so may require cessation of operations.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company received a Nasdaq delisting warning and may not be able to regain compliance.
• The company may never succeed in developing and commercializing its diagnostic tests and therapeutic products.
• Future profitability is not guaranteed, and failure to achieve or sustain profitability could depress the company's value.
• The company's ability to continue as a going concern is dependent on generating revenue and raising capital from financing transactions.
• If additional capital is not raised, the company may be forced to curtail or cease operations.

Future Outlook

The company expects to continue incurring losses and negative cash flows for the foreseeable future. It anticipates needing to raise further capital through equity or debt securities, strategic relationships, or grants to support future operations, as current cash and anticipated revenue may not be sufficient to sustain operations beyond August 2026. The company's business plan includes expansion for commercialization efforts requiring additional funding.

Management Comments

• Management concludes that there is substantial doubt about the Company's ability to continue as a going concern for a period of at least twelve (12) months subsequent to the issuance of the accompanying unaudited condensed consolidated financial statements.
• The Company will need to raise further capital through the sale of additional equity or debt securities or other debt instruments, strategic relationships or grants, or other arrangements to support its future operations, if revenue from operations does not significantly increase.
• If such funding is not available or not available on terms acceptable to the Company, the Company's current development plan may be curtailed.

Industry Context

StockSavvy.ai notes that bioAffinity Technologies operates in the competitive diagnostics and therapeutics space, focusing on early-stage lung cancer detection and other lung diseases. The company's reliance on flow cytometry and AI-driven analysis places it within a growing trend of technological integration in healthcare. However, the significant financial challenges and Nasdaq delisting concerns highlight the high-risk nature of early-stage biotechnology companies.

Comparison to Industry Standards

• The company's revenue growth for CyPath Lung is positive, but the overall revenue of $2.86 million for six months is modest compared to established diagnostic companies.
• The significant net loss and accumulated deficit are common for early-stage biotech firms investing heavily in R&D, but the going concern doubt is a critical concern.
• The Nasdaq bid price issue is a common challenge for micro-cap companies, often requiring reverse stock splits or significant capital raises to maintain exchange listing.

Legal Proceedings

• To date, the Company has no material pending legal proceedings.

Stakeholder Impact

• Shareholders face potential delisting from Nasdaq, which could reduce liquidity, limit market access, and negatively impact share value.
• The going concern doubt raises significant uncertainty for all stakeholders regarding the company's future viability.
• Employees may face job insecurity due to the company's precarious financial situation.
• Investors may experience a loss of their investment if the company cannot secure necessary funding or regain financial stability.

Next Steps

• Continue development and commercialization of CyPath Lung.
• Advance therapeutic discoveries for squamous and basal cell skin cancers.
• Seek strategic partners for therapeutic development.
• Address Nasdaq delisting concerns and attempt to regain compliance with minimum bid price requirements.
• Seek additional capital through equity or debt offerings, strategic relationships, or grants.

Key Dates

Recommendation

The company exhibits significant financial distress, including substantial doubt about its ability to continue as a going concern and a Nasdaq delisting warning. While there is some positive traction in CyPath Lung revenue, it is insufficient to offset the mounting losses and cash burn. The need for further capital raises, coupled with the risk of delisting, presents a high-risk investment profile.

Keywords

lung cancer diagnostics, CyPath Lung, flow cytometry, early detection, precision diagnostics, asthma, COPD, therapeutic discoveries